Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 15/20 | 0.61 |
| ▸ | NPC1 | O15118 | 14/20 | 0.61 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5934632 | 0.86 | TP53 (0.55) | RAB9ANPC1TP53MAPTSMN1; SMN2 | |
| SCHEMBL5174923 | 0.84 | NPC1 (0.84) | RAB9ANPC1TP53MAPTSMN1; SMN2 | |
| SCHEMBL5934674 | 0.82 | TP53 (0.51) | RAB9ANPC1TP53MAPTSMN1; SMN2 | |
| SCHEMBL30926503 | 0.80 | RAB9A (0.85) | RAB9ANPC1TP53MAPTSMN1; SMN2 | |
| SCHEMBL27181112 | 0.80 | RAB9A (0.85) | RAB9ANPC1TP53MAPTSMN1; SMN2 | |
| SCHEMBL5173569 | 0.80 | NPC1 (0.60) | RAB9ANPC1TP53MAPTSMN1; SMN2 | |
| SCHEMBL22699716 | 0.78 | TRPV1 (0.63) | RAB9ANPC1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL5934670 | 0.78 | MAPT (0.55) | RAB9ANPC1TP53MAPTSMN1; SMN2 | |
| SCHEMBL14082564 | 0.77 | RAB9A (0.76) | RAB9ANPC1TP53MAPTSMN1; SMN2 | |
| SCHEMBL5173449 | 0.77 | RAB9A (0.74) | RAB9ANPC1TP53MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165028-A1 | e.g. 4-bromo-N-(2,3-dihydro-1,4-benzodioxin-6-yl)benzamide; analgesics, neuropathic pain, inflammation, arthritis, rheumatic diseases, inflammatory bowel disorders, eye disorders, or bladder disorders, psoriasis, wounds, burns, allergic skin, herpes simplex | AMGEN, INC. | 2005-07-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165028-A1 | e.g. 4-bromo-N-(2,3-dihydro-1,4-benzodioxin-6-yl)benzamide; analgesics, neuropathic pain, inflammation, arthritis, rheumatic diseases, inflammatory bowel disorders, eye disorders, or bladder disorders, psoriasis, wounds, burns, allergic skin, herpes simplex | BDKRB2, TRPV1, HRH2 | RAB9A 1086/4885NPC1 3581/4885TP53 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.